A Hub for Corynebacterium glutamicum Research
Launching a New Platform Business with Corynebacterium glutamicum ATCC 13032
September 25, 2025
Administration Office,
Utilization of Carbon Dioxide Institute Co., Ltd..
Utilization of Carbon Dioxide Institute Co., Ltd. (Minato-ku, Tokyo; President & CEO: Dr. Hideaki Yukawa) is launching a new platform (contract research) business based on Corynebacterium glutamicum strain ATCC 13032 to run alongside its core business of CO2 utilization using hydrogen bacteria.
Dr. Yukawa developed the ingenious “growth-arrested bioprocess” using a different strain, Corynebacterium glutamicum R. Over the years, the bioprocess has demonstrated superiority over conventional fermentation methods in multiple instances.
The growth-arrested bioprocess is a totally different approach to chemical production: microbial growth is halted during the production phase. In contrast to conventional fermentations therefore, only the catalytic power of microorganisms is harnessed—much like chemical catalysts. The benefits are fascinating:
・Highly efficient production
・High tolerance to fermentation inhibitors
・Simultaneous utilization of multiple substrates
This breakthrough innovation was highly acclaimed and the basis upon which Green Earth Institute, Inc., a bio-manufacturing startup, was founded in 2011. In the same year, Dr. Yukawa was honored with a Society for Industrial Microbiology Fellow Award, one of the highest honors in applied microbiology. Since then, the concept of growth arrested bioprocess has expanded far and wide, particularly in Europe and America.
From R Strain to the Global Standard ATCC 13032
Research on the growth-arrested bioprocess with Corynebacterium glutamicum was initiated and developed using a strain with a scant record of industrial use. Concerns over bioprocess scale-up therefore worked against broader corporate interest.
The R strain and the globally much more widely utilized ATCC 13032 strain differ enough at the DNA level to result in significant structural differences. These reasons motivated a shift of focus at UCDI to ATCC 13032 strain upon which a recalibrated next-generation growth-arrested bioprocess with further enhancements in economic production was established.
Pursuing Extensive Collaboration
Through this next-generation growth-arrested bioprocess, we are opening new horizons for an industrial platform utilizing Corynebacterium glutamicum. We welcome R&D partners, both domestic and international, and call upon companies that have focused only on the R strain to date to join us in driving industrialization on a global scale.
As the “Liangshan Marsh” of Corynebacterium glutamicum research, we will actively seek to co-develop with researchers worldwide and continue our challenge to raise the profile of Japan-born technology to a global pedestal.
Utilization of Carbon Dioxide Institute Co., Ltd. (UCDI)
<Company Profile>
Head Office/ Research Institute | 14F, Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan |
Representative | Dr. Hideaki Yukawa(CEO/CSO) |
Established | August 12, 2015 |
Paid-in Capital | ¥247 million |
HP |
<Business Fields>
UCDI pursues research, development, and commercialization of innovative biotechnologies based on the capacity of UCDI® Hydrogen Bacteria to utilize CO₂ as a nutrient. 1 cell can multiply to 16 million individuals in 24 hours (1 gram of cells grows 16 tonnes of cell mass in 24 hours).
Within the three business fields of Protein (for human consumption), Bioenergy and SAF, and Chemicals (various chemical products), the company aims to contribute solutions that address problems of food shortage and dependence on fossil resources.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
このプレスリリースを配信した企業・団体

- 名称 株式会社CO2資源化研究所
- 所在地 東京都
- 業種 その他製品
- URL https://www.co2.co.jp/jp/top/